Search results
Humanity is continuously challenged by global disease burden from AMR and cancers. Available therapies are unable to address many of these issues. We are a group of highly experienced scientists with a single focus agenda to provide novel solutions to these health threats.
Bugworks™ Research India Pvt. Ltd. Center for Cellular & Molecular Platforms. National Center for Biological Sciences, TIFR GKVK Campus, Bellary Road, Bangalore 560 065, India.
News & Announcements. Dr. Anand Anandkumar, the co-founder and CEO of Bugworks Research Inc., was invited as a guest on an episode of the One World, One Health podcast. August 2, 2024 Published In One Health Trust Channel.
Shahul Hameed is an expert in medicinal chemistry and pharmaceutical sciences with more than 22 years of drug discovery and development experience in anti-infectives, anti-inflammatory and oncology drug discovery programs.
The AMR problem and the unmet need. The last novel class of antibacterial agents to be licensed was discovered in 1987. Antimicrobial Resistance (AMR) is one of the major challenges of our time, with devastating and long-lasting consequences.
Further validation of this unique feature is substantiated by the effectiveness of BWC0977 against fluoroquinolone resistant clinical isolates. The current study provides evidence of its potency against multi-drug resistant Gram negative &Gram positive pathogens & bio-defense pathogens.
Global Antibiotic R&D Partnership (GARDP) and Bugworks Research Inc. are joining forces to co-develop an innovative compound (BWC0977) with broad-spectrum antibiotic activity against multidrug-resistant bacteria that cause life-threatening infections. June 11, 2024 Published in bugworksresearch.com.
Introduction : Developing an ODE Model. in silico models based on Systems biology, allow us to have an in-depth insight into complex biological networks and their interactions. Two commonly followed approaches for creating such biological models are: Flux Balance Analysis (FBA) and Dynamic Simulation Analysis using ODE.
ained from Dr Evgeni Sokurenko; Univ. of Washington).OBJECTIVESAssess PK, tolerability and efficacy of BWC0977 in the optimized ascending UTI model in normal and streptozotocin (. TZ) -induced diabetic mice using E. coli ST131 H30R s. blood glucose levels to evaluate diabetic induction.
email: vasanthi@bugworksresearch.com Antimicrobial resistance has now emerged as a major threat worldwide impeding efficacious treatment of hospital associated as well as community acquired infections. No new drug has been developed in the last five decades to address the problem of AMR, especially due to Gram-negative infections.
